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ABSTRACT 
Background: Up to 55% of patients administered ketamine, experience an emergence 
phenomena (EP) that closely mimics schizophrenia and increases their risk of injury. While 
genetics accounts for about 50% of severe adverse drug reactions, no studies have investigated 
genetic association of ketamine-induced EP in healthy patients. Ketamine is metabolized by CYP 
2B6 enzymes and CYP 2B^8^ allele significantly alter ketamine metabolism. In addition, 
ketamine exerts most of its effects by inhibiting the N-methyl-D-aspartate receptor (NMADR), 
and NMDAR genes (GRIN2B) are associated with learning and memory impairment and 
schizophrenia.  
Purpose: To investigate the relationship between CYP2B6*6 and GRIN2B single nucleotide 
polymorphisms (SNPs) and ketamine-induced emergence phenomena (EP).  
Methods: This cross-sectional pharmacogenetic study recruited 75 patients having minor 
orthopedic, hand, foot, anorectal surgeries from two outpatient surgical centers. EP was 
measured with the Clinician Administered Dissociative State Scale (CADSS). DNA was 
genotyped using standard Taqman assays and protocols.  Genetic association of CYP2B6*6 and 
GRIN2B (rs1019385 & rs1806191) SNPs and ketamine induced EP occurrence and severity were 
tested using multivariate logistic and linear regression, adjusting for age, ketamine dose, duration 
of anesthesia, and time since ketamine administration.  
Results: Forty-seven patients (63%) received ketamine and were genotyped.  Nineteen EP cases 
were identified (CADSS > 4), leaving 28 non-EP controls. For our population, CADSS has an 
internal consistency reliability Cronbach’s alpha of 0.82, and could reliably distinguish ketamine 
from non-ketamine cases. Occurrence and severity of EP were not associated with CYP2B6*6 or 
GRIN2B (p > 0.1). Models removing genotype and containing age, ketamine dose, duration of 
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anesthesia, and time since ketamine administration significantly predicted EP occurrence (p = 
0.001) and severity (p = 0.007). Presence and severity of EP did not affect patient satisfaction 
with care. 
Discussion: Younger age, higher dose and longer duration of anesthesia significantly predicted 
EP occurrence and severity among our sample. This study provides effect size estimates useful 
for the design of adequately powered future genetic association studies. The feasibility of 
recruitment from patients undergoing elective, outpatient surgeries and ease of post-operative EP 
assessment with CADSS supports our approach. However, the small sample size may have 
limited about ability to determine significant differences.  
Conclusion: Fully powered studies are needed to investigate this important phenomena. 
Determining factors for anesthesia-related EP symptoms may reduce risks and costs associated 
with this adverse medication effect. 
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EXPLORING THE PHARMACOGENETICS OF KETAMINE-INDUCED EMERGENCE 
PHENOMENA 
Ketamine is an N-methyl-D-aspartate receptor (NMDAR) antagonist that is recognized 
by the World Health Organization (WHO) as an essential drug in any basic health care system 
(World Health Organization, October 2013), and has been used in various settings from 
battlefields (Dickey, Jenkins, & Butler, 2012), developing countries (Morgan & Curran, 2012) to 
critical care units in tertiary care centers (Mohrien, Jones, MacDermott, & Murphy, 2014). It is 
an ideal anesthetic because it causes rapid loss of consciousness, amnesia, analgesia, cardio-
pulmonary stability, and treatment of mental disorders (Aroni, Iacovidou, Dontas, Pourzitaki, & 
Xanthos, 2009; Mion & Villevieille, 2013; Zarate, Brutsche, Ibrahim, et al., 2012; Zarate, 
Brutsche, Laje, et al., 2012). Unfortunately, ketamine-induced emergence phenomena (EP) 
which occurs in up to 55 percent of patients (Kumar, Bajaj, Sarkar, & Grover, 1992) limits its 
clinical use (L. J. Mason, 2004).   EP is characterized by euphoria, vivid dreams, illusions, 
delirium, and hallucinations (Aroni et al., 2009; Stoelting & Hillier, 2006; Xu & Lipsky, 2014). 
Patients experiencing EP are at higher risk of injury, longer hospital stay, require more nursing 
care, and report lower satisfaction with care (Hudek, 2009; O'Malley, 2014; Stoelting & Hillier, 
2006; Wells & Rasch, 1999). In addition, EP increases cost to patients, providers, and the health 
care system (Franco, Litaker, Locala, & Bronson, 2001). Research efforts to date have focused 
on identifying pharmacological interventions to prevent EP (Stoelting & Hillier, 2006). There is 
no definitive treatment or predictive tools to identify patients who will develop EP. 
While several factors contribute to individuals’ response to drugs, it is believed that 
genetic predisposition accounts for about 50 percent of severe adverse drugs reactions (ADRs) 
(Chidambaran, Ngamprasertwong, Vinks, & Sadhasivam, 2012; Hijazi & Boulieu, 2002; 
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Yanagihara et al., 2001). Single nucleotide polymorphisms (SNPs), which are the most common 
type of genetic polymorphisms, have been associated with alterations in drug metabolism, 
efficacy, and response. Two genes of interest in this phenomenon are CYP2B6 and GRIN2B. 
Ketamine is metabolized primarily by the enzymes encoded by CYP 2B6 (Hijazi & Boulieu, 
2002; Portmann et al., 2010; Yanagihara et al., 2001), and in-vitro studies have shown that SNPs 
in CYP2B6*6 significantly alters its metabolism (Y. Li et al., 2013).  The signs and symptoms of 
EP closely mimic those of schizophrenia and ketamine is frequently used as a pharmacologic 
model for this disorder. Ketamine exerts most of its central nervous system (CNS) effects 
through the N-methyl-D-aspartate receptor (NMDAR), and its effects on this pathway are the 
bases for the glutamatergic theory of schizophrenia (Javitt, 2010). Genetic polymorphisms in the 
NMDAR genes, like GRIN 2B, have been associated with learning and memory impairment, and 
schizophrenia (Frohlich & Van Horn, 2014; Xu & Lipsky, 2014). Thus, I hypothesize that 
ketamine-induced EP may be related to genetic variations in CYP2B6 and GRIN2B.  
The purpose of this exploratory study is to investigate the relationship between CYP 2B6, 
and GRIN2B polymorphisms and the incidence and severity of ketamine-induced EP in healthy 
patients undergoing scheduled ambulatory surgical procedures. The specific aims of this study 
are:  
Aim 1: Explore genetic association between CYP2B6 SNPs and ketamine-induced EP. As 
common functional CYP2B6*6 SNPs affect ketamine metabolism, I hypothesize genetic 
association with risk alleles of CYP2B6*6 and greater incidence and severity of EP. Leukocyte 
DNA and Clinician Administered Dissociative State Scale (CADSS) will be used to determine 
genetic polymorphisms and the incidence and severity of EP, respectively. Potential effect 
modification by midazolam will be explored.  
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Aim 2: Explore genetic association between GRIN2B SNPs and ketamine-induced EP. Because 
ketamine is an NMDAR antagonist that induces glutamate release in the CNS and glutamate 
hypo-function correlates with psychotic symptoms, EP mimics schizophrenia (Frohlich & Van 
Horn, 2014) . Moreover, given that GRIN2B SNPs are associated with schizophrenia, learning, 
and memory disorders (Demontis et al., 2011; D. Li & He, 2007), I hypothesize that patients 
with common SNPs in GRIN2B will develop similar psychological responses to ketamine. 
Potential effect modification by midazolam will be explored.  
Aim 3: Explore if GRIN2B genes interact with CYP 2B6 in predicting the incidence and severity 
of ketamine induced EP. Given that SNPs in CYP2B6*6 allele alter ketamine metabolism, and 
SNPs in GRIN2B alter NMDAR function, I hypothesize that patients who rapidly metabolize 
ketamine and have decreased NMDAR function will have reduced incidence and severity of EP. 
Aim 4: Evaluate the validity of the CADSS in discriminating EP behaviors associated with 
ketamine. 
The correlation between the incidence and severity of ketamine-induced EP, GRIN2B and 
CYP2B6 genetic polymorphism in healthy patients has not been studied. An a priori knowledge 
of patients that will develop ketamine-induced EP based on their genetic make-up may have 
significant future implications for anesthesia care, procedural sedation, acute and chronic pain 
management (including cancer pain), and management of mental disorders. This study will 
provide preliminary data necessary for the development of a program of research to improve our 
understanding of risk for EP and identify genetic predisposition to EP, both of which could lead 
to improved patient outcomes. Advancing the nurse anesthesia profession through 
pharmacogenetic research is my dream.  
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BACKGROUND AND SIGNIFICANCE 
Clinical Uses of Ketamine 
First introduced into clinical practice about 50 years ago (Domino, 2010), ketamine  is an 
N-methyl-D-aspartate receptor (NMDAR) antagonist that is used for induction of anesthesia, 
procedural sedation, pain management and treatment of major depression (Aroni et al., 2009; 
Mion & Villevieille, 2013; Zarate, Brutsche, Ibrahim, et al., 2012; Zarate, Brutsche, Laje, et al., 
2012). The NMDAR is a heteromeric voltage-gated inotropic receptor containing two NR1 
subunits in association with two NR2 (A, B, C, or D) and/or NR3 (A or B) subunits. Activation 
of this receptor requires glycine (an inhibitory neurotransmitter) and glutamate (an excitatory 
neurotransmitter. Ketamine non-competitively blocks the excitatory effects of glutamate (its 
principal neurotransmitter) by binding to the NR2 subunit (Monaghan & Jane, 2009).  This leads 
to depression of sensory association in the cerebral cortex, limbic system, and thalamus, resulting 
in rapid loss of consciousness (Aroni et al., 2009).  
Unlike other anesthetics such as propofol, patients under ketamine-induced loss of 
consciousness maintain spontaneous respiration and protective airway reflexes. In addition, its 
sympathomimetic effects lead to hemodynamic stability and bronchodilation. Thus, it is the 
preferred anesthetic in patients with severe asthma (Lau & Zed, 2001) and hemodynamic 
instability such as  hypovolemia, cardiogenic shock and constrictive cardiac disorders (Aroni et 
al., 2009). It is equally the sedative of choice in situations where airway management equipment 
is not readily available (e.g. battlefields (Dickey et al., 2012), developing countries (Morgan & 
Curran, 2012), endoscopy and radiology suites (K. P. Mason et al., 2002).  
Despite the fact that ketamine works on other receptors, most of it effects are on the 
NMDAR. The NMDAR has a significant role in acute and chronic pain management (Monaghan 
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& Jane, 2009). Ketamine has an opioid sparing effect. A Cochrane review show that ketamine  
decreases post-operative opioid requirement (Bell, Dahl, Moore, & Kalso, 2006) and it is a 
potential breakthrough for management of opioid refractory cancer pain (Bell, Eccleston, & 
Kalso, 2012; Bredlau, Thakur, Korones, & Dworkin, 2013). It also effective in the management 
of phantom limb pain (Alviar, Hale, & Dungca, 2011),  fibromyalgia, and chronic regional pain 
syndrome (Correll, Maleki, Gracely, Muir, & Harbut, 2004).  
Ketamine is administered be several routes: intravenous, subcutaneous, intramuscular, 
per-rectal, sub-lingual, epidural and inhalations. It is therefore a good induction drug for 
uncooperative patients, children, and patients with burns who have limited IV access (Aroni et 
al., 2009). Its bioavailability via the oral route is low (about 20%) because ketamine undergoes 
extensive first pass metabolism. It is metabolized primarily by the hepatic cytochrome p450 2B6 
(CYP2B6) enzyme with minor contributions from CYP3A4 and CYP2C9 (Hijazi & Boulieu, 
2002; Yanagihara et al., 2001). However, renal and hepatic functions do not appear to 
significantly affect its metabolism and elimination (Mion & Villevieille, 2013). Thus, I 
hypothesized that genetic alternations in the structure and function of the primary drug-
metabolizing enzyme (CYP2B6) affect the incidence and severity of ketamine induced EP. 
Ketamine Induced Emergence Phenomena 
Ketamine-induced emergence phenomena (EP) refers to the psychological 
(pyschodysleptic or psychedelic) effects experienced by some patients as they recover from 
ketamine induced loss of consciousness (Curran & Morgan, 2000; Mion & Villevieille, 2013; 
Morgan & Curran, 2012). The incidence of EP varies from 5 to 55 percent (Kumar et al., 1992; 
White, Way, & Trevor, 1982b) and it remains the main reason for ketamine’s limited clinical use 
(L. J. Mason, 2004). Risk factors of EP include age>15 years, doses >2mg/kg IV, rapid 
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administration, female gender, and mental disorders (O'Malley, 2014; Sdrales, 2013; Stoelting & 
Hillier, 2006). EP is a significant adverse drug reaction because it prolongs hospital length of 
stay, increases risk of injury to patients and staffs, and increases nursing and medical staff 
requirements (Hudek, 2009). In addition, patients who experience EP report decreased 
satisfaction with care, and incur additional cost (Uezono et al., 2000). It is equally costly to the 
institution and the entire health care system (Franco et al., 2001). 
Nature of Ketamine Induced Emergence Phenomena 
Ketamine-induced emergence phenomena (EP) is frequently used interchangeably with  
ketamine-induced delirium (Kumar et al., 1992; Lohit, Srinivas, & Chanda-Kulkarni, 2011; 
Treston et al., 2009). While ketamine induced emergence phenomena includes the wide range of 
psychological symptoms (from euphoria to combative hallucination) reported by patients 
following ketamine administration,  ketamine induced delirium is more restrictive in that it 
describes patients who experience agitation, restlessness and combative behavior without being 
aware of their surroundings (Treston et al., 2009; Uezono et al., 2000). EP is characterized by 
euphoria, floating sensation, vivid dreams, disorientation, auditory and visual illusions, which 
may progress to delirium and hallucinations and a sense of dissociation from the environment 
(Cunningham & McKinney, 1983; Domino, 2010; Siegel, 1978). Clinically, patients appear 
semi-conscious (eyes open), and breathe spontaneously with random movements, but are unable 
to process and respond to sensory and noxious stimuli.  
Several studies have investigated the nature of ketamine-induced EP. Using a 
psychonautic approach (a methodology of describing and explaining the subjective effects of 
drugs), Newcombe (2008) described a “ketamine trip” to the “ketamine world”. In the ketamine 
world (also known as K- world), subjects experience “strange things [that] appear to be giving 
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information …with distinct auditory hallucinations” (p. 212).  The psychonaut described a sense 
of dissociation from the environment, an euphoric, energetic state  with visual and auditory 
distortions that lasted about an hour or two (Newcombe, 2008). A phenomenological study of 
recreational users of ketamine, found that ketamine induced  distortions in perceptions similar to 
negative symptoms of schizophrenia:  flat affect, poverty of speech, thought disorders and  
delusions but did not cause hallucination (Pomarol-Clotet et al., 2006).  Pomarol-Clotet and 
colleagues (2006)  described distortions in body image and objects (sharpness, color and size), 
which some authors have attributed to hallucinations (J. H. Krystal, Karper, Seibyl, & et al., 
1994). In fact, Krystal and Colleagues (1994) found that sub-anesthetic doses of ketamine 
produced cognitive impairment, positive and negative psychotic symptoms. As a result, ketamine 
is used as a pharmacological model for schizophrenia (Frohlich & Van Horn, 2014).  
Using a single photon emission tomography (SPET) scan of healthy volunteers with 
highly specific NMDAR ligand, Stone and Colleagues (2008) discovered that ketamine produced 
negative psychotic symptoms by binding to the NMDAR, while the positive psychotic  
symptoms where related to ketamine blood  levels. However, they did not find any relationship 
between positive and negative psychotic symptoms (Stone et al., 2008). In a subsequent study 
using magnetic resonant imaging, Stone and colleagues (2012) described ketamine-induced the 
release of glutamate from the anterior cingulated cortex. The ketamine induced release of 
glutamate correlates with positive psychotic symptoms (Stone et al., 2012). A comprehensive 
review of the literature on ketamine as a model for schizophrenia found that ketamine-induced 
EP correlates with negative and positive psychotic symptoms of schizophrenia (Frohlich & Van 
Horn, 2014). 
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Current Management/Prevention of EP 
Physical and chemical restraints have been used to manage EP (Wells & Rasch, 1999). 
Benzodiazepines such as midazolam are frequently co-administered with ketamine to prevent EP 
(Cartwright & Pingel, 1984; White, Way, & Trevor, 1982a). Several randomized controlled trails 
comparing midazolam-ketamine against ketamine alone did not find any significant difference 
(Sherwin, Green, Khan, Chapman, & Dannenberg, 2000; Wathen, Roback, Mackenzie, & 
Bothner, 2000). More recently, a double blind randomized placebo-controlled trial found that co-
administration of midazolam significantly reduced the incidence of EP (Sener, Eken, Schultz, 
Serinken, & Ozsarac, 2011). But unlike the Sherwin and Colleagues (2000) study that reported 
the psychometric properties of their measurements, Sener and colleagues (2011) did not utilized 
any developed instruments to measured EP. They measured EP “as any moaning, screaming, 
cursing, unpleasant dreams, or unpleasant hallucinations, regardless of severity” (Sener et al., 
2011, p. 110), some of which could be signs of pain not EP. Unfortunately, no pain scores were 
reported. Thus, the co-administration of  midazolam with ketamine remains a reasonable option 
since midazolam does potentiates amnesia and decreases anxiety (Green, Roback, Kennedy, & 
Krauss, 2011).  
 Other drugs that have been investigated to prevent/manage EP and found to have mixed 
results include haldol (Amr, Shams, & Al-Wadani, 2013), dexmedetomidine (Levanen, Makela, 
& Scheinin, 1995) and propofol (Alletag, Auerbach, & Baum, 2012; Andolfatto & Willman, 
2010). The use of music to attenuate ketamine induced EP, did not show any significant 
difference (Kumar et al., 1992). To date, there is neither a definitive treatment for EP, nor a 
clinical tool to predict which patient will develop EP. As Edward Domino eloquently described 
ketamine  “beware of that tiger… it needs to be tamed” (Domino, 2010, p. 683).  
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CONCEPTUAL FRAMEWORK 
Genetic bases of variability in drug response 
Historically, clinicians have depended on the pharmacological properties of drugs (such 
as size of molecules, charge, solubility, concentration, volume of distribution, and mode of 
excretion) to predict patients response to medications.  And despite tremendous advances in our 
knowledge of pharmacology, patients are still at risk for suffering adverse drug reactions due to 
inter-individual variability in their response to drugs (Wang, 2010). While several factors 
influence individuals’ response to medications, genetic predisposition accounts for about 50 
percent of severe adverse drug reactions (SADRS) (Chidambaran et al., 2012). The genetic base 
of inter-individual variability in drug response was first established when Kalow and colleagues 
(1957) discovered that an atypical form of the enzyme responsible for metabolizing 
succinylcholine (butyrylcholinesterase, also known as plasma or serum cholinesterase) was 
responsible for prolonged apnea after succinylcholine administrations. In 1959, Vogel coined the 
term “pharmacogenetics” to describe the research that combines our knowledge of 
pharmacologic properties of drugs and genetic variability to determine onset, duration, 
emergence, and response to medications (Altman, Flockhart, & Goldstein, 2012).  
Advances in molecular biology have shown that variation in nucleotide base sequences 
on DNA, can result in alterations in the structure and function of proteins. The most common of 
these genetic variations are single nucleotide polymorphisms (SNPs). SNPs occur in more than 1 
percent of the population and result when fragments of DNA differ between individuals by one 
specific nucleotide in a DNA sequence. SNPs that result in amino acid changes (during 
translation), are referred to non-synonymous variations, while those that do not alter the amino 
acid are referred to as synonymous variations. Genetic variations (SNPs) that result in non-
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Enzymes variants that increase drug metabolism will decrease the availability of parent drug at 
the target site, while increasing the availability of its metabolite. Similarly, enzyme variants that 
decrease metabolism will increase the concentration of the parent drug, while decreasing the 
accumulation of its metabolites. These have implications for the development of adverse drug 
reactions (Altman et al., 2012; Roden & George Jr, 2002; Wang, 2010).  
As mentioned above, ketamine is metabolized primarily by enzymes coded by CYP2B6 
with minor contributions from CYP 3A4 and CYP 2C9 (Hijazi & Boulieu, 2002; Yanagihara et 
al., 2001). CYP2B6 has many SNPs that alter drug action (U. M. Zanger & K. Klein, 2013). 
Specifically, CYP2B6*6 haplotype has two SNPs that result in non-synonymous amino acid 
substitutions, Gln172His (rs3745274, c.516G>T) and Lys262Arg (rs2279343,785A>G ) in exons 
4 and 5 respectively (U. M. Zanger & K. Klein, 2013). In vitro studies show that CYP2B6*6 
allele significantly affects ketamine metabolism (Y. Li et al., 2013). Similarly, SNPs in the same 
allele (CYP2B6*6) significantly alter the N-demethylation of methadone (another NMDAR 
antagonists) (Dennis, Bawor, Thabane, Sohani, & Samaan, 2014; Gadel, Crafford, Regina, & 
Kharasch, 2013; Kharasch & Stubbert, 2013) and increases CNS side effects in HIV-infected 
patients treated with efavirenz (Gounden, Van Niekerk, Snyman, & George, 2010). However, 
among patients with treatment resistant depression and bipolar disorder, Zarate and colleagues 
(2012) did not find any relationship between CYP alleles and EP (Zarate, Brutsche, Laje, et al., 
2012). History of mental disorder is a risk factor of EP (Stoelting & Hillier, 2006), and to date, 
no study has investigated the correlation between CYP alleles and EP in healthy patients.  
Pharmacodynamics variability:  
The term pharmacodynamic variability refers to “the relationship between the drug 
concentration and its effects” (Roden & George Jr, 2002, p. 39). Individuals with the same 
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concentration of drug in blood and target tissue have different responses to the drug. Such 
individual differences can be accounted by variability in tissue (target protein) response to the 
drug (Altman et al., 2012; Daly & Arranz, 2012; Roden & George Jr, 2002).  
Ketamine binds to the NR2 subunit of the NMDAR, and blocks the action of glutamate. 
Functional MRI studies have shown that it induces glutamate release in a manner similar to its 
release in NMDAR hypo-function (Frohlich & Van Horn, 2014) . NMDAR hypo-function and 
glutamate hyperactivity are the molecular bases of schizophrenia (Javitt, 2010). In addition, 
genetic polymorphisms in the glutaminergic pathway have been associated with NMDAR hypo-
function and symptoms of schizophrenia, learning, and memory disorders (Frohlich & Van Horn, 
2014; D. Li & He, 2007; Xu & Lipsky, 2014). Two SNPs (T200G (rs1019385), 4197T/C (D. Li 
& He, 2007) and rs1806194 (Demontis et al., 2011)) in the NMDAR gene (GRIN2B) have been 
linked to schizophrenia in susceptible individuals. Thus, ketamine-induced EP may be related to 
NMDAR- NR2B subunit function.  
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RESEARCH APPROACH 
Design 
An exploratory cross sectional design with candidate gene association approach will be 
utilized to investigate the relationship between CYP2B6 and GRIN2B polymorphisms and 
ketamine-induced EP in relatively healthy patients undergoing anorectal, orthopedic, hand or 
foot surgery.  
Sample and Setting 
Participants in this study will comprise a convenience sample of 135 patients presenting 
for ambulatory hand or foot surgery at the University of Massachusetts Memorial Health Care: 
University, Memorial, and Hahnemann Campuses. The power to detect statistical significance 
depends on the number of SNPs, allelic frequencies of each SNP, effect size and study design 
(Ross, Anand, Joseph, & Pare, 2012, p. 9). Based on additive and dominant genetic models of 
inheritance, a sample of 135 with  a population allelic frequency of 25%, 80% power, and 0.05 
significance,  can  to detect a relative risk of 2  (Schmidt, 2007). This detectable relative risk of 2 
converts to an approximate odd ratio of 2 (Zhang & Yu, 1998), because the incidence of EP in 
patients not exposed to ketamine is expected to be low (< 10%). Thus, this sample size is 
powered to detect an EP association with an observed odd ratio of about 2.5 during procedural 
sedation (Elia & Tramer, 2005). Results from this study may inform larger studies investigating 
this important phenomenon 
Limited difficulty is anticipated in obtaining a sample of 135 patients because these two 
facilities perform over 2000 hand and foot surgical procedures yearly on relatively healthy 
patients. The PI is employed as a Certified Registered Nurse Anesthetist at this hospital and has 
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letters of support from the Chair of the Anesthesia Department, the Perioperative Medical 
Directors, and Directors of Perioperative Nursing Services.  
Table 1 
Inclusion and Exclusion Criteria with Rationale  
 Inclusion Rationale 
ASA Class 1 and 2  Focus on healthy patients  
Read and write English  Unable to provide interpreter in multiple languages 
Adult 18 years and older Children are less likely to experience EP (Frohlich & Van Horn, 
2014) 
Exclusion Rationale 
History of mental disorder Increase risk of psychological effects (Stoelting & Hillier, 2006) 
Allergic to Ketamine Ensure participants safety 
Contraindications to ketamine 
e.g. uncontrolled hypertension, 
history of ketamine addiction 
Sympathomemitic effects of ketamine can increase blood pressure 
- Prevent possible relapse in participants 
Currently taking Rifampicin, 
Dilantin or Phenobarbital  
-CYP2B6 enzyme inducers(Ulrich M Zanger & Kathrin Klein, 2013) 
may alter the ketamine metabolism 
Pregnancy The safety of ketamine during pregnancy has not been established. 
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Procedures 
Once Institutional Review Board (IRB) approval is obtained from the University of 
Massachusetts Worcester, the PI will communicate specifics of the study  plan to all involved 
parties including the Chair of the Anesthesia Department, Directors of Perioperative Services, 
and Nurse Managers. This letter will review the purpose of the study and the procedures 
necessary to collect data. The letter will be followed with a presentation to members of the 
anesthesia department (Anesthesiologists and CRNAs) during regularly scheduled weekly grand 
round meetings. All providers will be given the chance to ask questions about the study and 
study pamphlets will be distributed. A similar meeting will be held with Surgical Admissions 
Care Unit (SACU) and Post-Anesthesia Care Unit (PACU) nurses at both campuses. All nurses 
will be given the chance to ask questions about the study and study pamphlets distributed. The 
study has been approved by all hand and foot surgeons. A HIPAA waiver will be obtained from 
the IRB to access the list of potential participants scheduled for surgery and their pre-operative 
assessment. The pre-operative assessment will be used to verify inclusion/exclusion criteria. 
Potential participants will be given a handout describing the study during their preoperative visit 
at the pre-surgical evaluation (PSE) clinic. On the eve of the scheduled surgical procedure, the PI 
will call potential participants to discuss the study.  
When the potential participants present for surgery they will undergo routine pre-
procedure assessment by the SACU nurse and anesthesia provider. After this, the PI will discuss 
the study with them and review all components of the consent form, including the study purpose, 
procedures, potential risks and benefits. The PI will allow time to answer all questions and 
willing participants will be asked to read and sign the IRB-approved informed consent form. 
Consenting participants will be asked to complete a paper and pencil demographic form with 
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information about their age, race, smoking history, alcohol use, highest level of education and 
gender. Completed forms will be returned to the PI. Preoperative sedative will be administered at 
the discretion of the anesthesia provider. Standard of care allows for many alternative anesthetics 
to be used to achieve intra-operative sedation. The anesthesia provider will determine the choice 
of anesthetic.  
Clinician Administered Dissociative State Scale (CADSS) 
Ketamine-induced EP is most likely to occur within one hour of emergence from 
anesthesia (Sdrales, 2013). Thus, within one hour of participants’ arrival in the PACU, the PI 
will administer the CADSS, a validated instrument that assesses a dissociative state. This scale 
contains 28 (23 subjective and 5 objective) items followed by 5 anchors. The anchors are rated 
from 0 (no symptoms) to 4 (extreme symptoms). A total score of >4 on CADSS signifies a 
dissociative state (Bremner, 2014). Initial psychometric testing reported an inter-rater reliability 
of 0.92 (p <.01), an internal consistency Cronbach’s alpha of 0.94 (p<.05), and a construct 
validity correlation of 0.48 and 0.42 with Dissociative Experiences Scale (DES) and Structured 
Clinical interview for DSMIIIR-Dissociative Disorder (SCID-D) respectively (Bremner et al., 
1998). CADSS has been used in many studies investigating the psychological effects of ketamine 
(Curran & Morgan, 2000; Dakwar et al., 2014; J.H. Krystal et al., 1998; Pomarol-Clotet et al., 
2006; Radant, Bowdle, Cowley, Kharasch, & Roy-Byrne, 1998; Zarate, Brutsche, Laje, et al., 
2012). In this study, two additional questions (items 29 and 30) will be added in an attempt to 
capture the participants’ overall impression of the anesthetic.  
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Measures, Data Collection and Laboratory Methods 
The PI will review the patient record and collect data on perioperative medications and 
dosages after completion of the CADSS. The PI will abstract data on height, weight, substance 
abuse, current medications and dosages from the medical record. Patients who received 
additional sedatives such as propofol, opioids, haldol, and droperidol will be used as control 
cases to determine the discriminatory validity of CADSS for ketamine-induced EP. 
All patients who receive ketamine will have two vials of 5ml venous blood collected in 
an EDTA tube, prior to the removal of the intravenous line. If aspiration of the IV access fails to 
return blood, a direct venous puncture will be used. One vial will be used for genotype, while the 
second vial will be stored for future studies. Each blood tube will be labeled with a study ID 
number in front of the participant. Leukocyte DNA is stable in EDTA at 4oC for 72hours. 
Samples will be frozen on ice and transported to UMass core laboratory, where it will be stored 
frozen at -20 degrees centigrade until analyzed. The freezer will be locked, and only the PI and 
laboratory manager will have access to the specimen. A hand-written table containing coding 
system (study ID number and patient’s name) will be kept in a locked filing cabinet. Only the PI 
will have access to this cabinet. This will be the only source of data to match the participants to 
the study ID.  
Genetic Analysis 
Genomic DNA for SNP identification will be extracted using QIAamp DNA Blood mini 
kit (Qiagen, USA). When ready for analysis, the blood samples will be delivered to a UMass 
based molecular biology core laboratory per standard biohazard transfer procedures. Samples 
will be thawed and DNA extracted and purified according to the manufacturer’s instructions. 
DNA will be quantified and assessed for quality using Nanodrop spectrophotometers. CYP 2B6 
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SNPs (rs3745274, and rs2279343) and GRIN2B SNPs (rs1019385 and rs1806191) alleles will be 
genotyped using Taqman Genotyping Assays (Applied Biosystems) (see Table 2. Gene/SNPs). 
The laboratory personnel will be blinded to the participants’ demographic information and 
phenotype. All samples will be run against control standards and the genotype call rate/error rate 
obtained and reported. As an additional control, 10% of randomly selected samples will be re-
genotyped for each of the genes. All unused samples will be stored in a locked freezer after data 
analysis at UMass.  
Table 2 
Gene/SNP variants   
Gene SNP (Polymorphic/ 
mutation) 
Functional 
change 
Chr Location* Alleles 
(minor/ wild-
type) 
MAF 
(HapMap) 
 
CYP2B6*6 
rs3745274 (missense) Gln172His 19 41006936 T/G 27% (Cau), 
42% (Yrb) 
rs2279343 (missense) Lys262Arg 19 41009358 G/A 21% (Cau), 
46% (Yrb) 
 
GRIN2B 
rs1019385 
(polymorphic) 
-- 12 13981909 T/G 50% (Cau), 3% 
(Yrb) 
rs1806191 
(synonymous) 
His440His 12 13563704 A/G** 44% (Cau), 
84% (Yrb)** 
SNP, single nucleotide polymorphism; Gln, glutamine; His, histidine; Lys, lysine; Arg, arginine; 
Cau, Caucasian/European; Yrb, Yoruban/African American   
*NCBI Build GrCh38 (base pair location of SNP) 
**Minor allele for rs1806191 is G; any race-stratified analyses will account for the G allele as 
the minor variant.  
Statistical Analysis 
Data will be imported into SPSS (version 21) for analysis. Double entry will be used to 
ensure accuracy. Demographic data and genetic allele frequencies will be analyzed and presented 
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as means (continuous variables) and frequencies (categorical variables). Descriptive statistics 
(frequencies, means, standard deviations, and percentages) will be calculated for all study 
variables as appropriate to the level of data. For continuous variables, mean, median, skewness, 
standard error of the mean, standard deviation, and histograms will be calculated. Frequencies 
will be run on all categorical variables. All continuous variables will be checked for normal 
distribution by calculating Fisher's measure of skewness. Internal consistency reliability will be 
evaluated using Cronbach's alpha as appropriate. 
The occurrence of ketamine-induced EP will be analyzed as a categorical variable, 
determined by a total CADSS score of ≥4, per the instruments’ scoring criteria for EP. Severity 
of ketamine-induced EP will be analyzed as a continuous variable (total score on CADSS). 
Leukocyte genomic DNA will be used to determine participants’ genotypes for CYP2B6 and 
GRIN2B genes. Each genetic marker (SNP) will consist of a biallelic locus. For this purpose, 
alleles will be represented d (wild type allele) and D (minor or risk allele). Possible genotypes 
will be d/d, d/D and D/ D. All SNPs will be tested for independence and stability in the 
population using the Hardy-Weinberg Equilibrium (HWE) equation. 
Aims 1 and 2: Investigate the genetic association between SNPs and incidence and severity of 
Ketamine-induced EP. 
All hypotheses are two-tailed and tested at a 0.05 significance level. Multiple testing will 
be controlled with Bonferroni correction. All self-reported racial/ethnic groups will be analyzed 
together, except for analyses involving rs1806191, as the minor allele is opposite in 
Yoruban/African American populations, requiring sub-stratified analysis of this variant by race. 
All SNPs will be evaluated independently, using both additive and dominant genetic 
models. Both the dominant and additive genetic models use tests with one degree of freedom, 
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which are generally more powerful than a wide range of genetic models. The additive model 
tests the effect of each risk allele in the SNP in a linear fashion, such that having 1 risk allele 
(d/D) has a greater effect than having zero risk alleles (d/d), and having 2 risk alleles (D/D) 
shows a greater effect than having only 1 (d/D). We will employ chi-square 2 x 3 contingency 
table to compare additive genotype counts (d/d, d/D, DD) against EP status (positive EP 
occurrence, no EP). Results will be expressed as odds ratios of the incidence of EP by genotype 
status.  
The dominant model tests the effect of having at least one copy of the risk alleles in the 
SNP on the occurrence of EP, such that genotypes d/D and d/d are combined and compared to 
wild-type homozygous (D/D) individuals. A chi-square 2 x 2 contingency table will be used 
compare genotype counts (d/d and d/D vs. D/D) and EP status. Results will be expressed as odds 
ratios of the incidence of EP by genotype status (carriers of d vs. DD). To determine whether 
genotypes predict severity of EP, linear regression models will test the additive and dominant 
genetic effects on the total CADSS score (range: 0-112) in EP incident cases (CADSS > 4), 
controlling for age, gender, dose of ketamine, duration of surgery, and use of midazolam. 
In order to evaluate the impact of concurrent midazolam administration and other 
potential confounders on genetic associations with ketamine-induced EP incidence, logistic 
regressions will also be performed using both additive and dominant genetic models as described 
previously. All SNPs will be tested independently for their prediction of EP occurrence (0,1), 
controlling first for midazolam alone, then in separate models controlling for age, sex, dose of 
ketamine, duration of surgery, and use of midazolam. 
Finally, all analyses will be conducted similarly in the non-ketamine exposed participants 
in order to explore comparisons. This may further aid in distinguishing exposure- and/or genetic-
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mediated effects. For example, if significant genetic associations are found in both ketamine- and 
non-ketamine exposed groups, it may provide preliminary evidence of genetically-mediated EP 
that is independent of ketamine. Likewise, lack of significant genetic associations in non-
exposed groups compared to significant associations in ketamine-exposed groups adds more 
formal evidence in this pilot design.  
Aim 3. Investigate if GRIN2B genes interact with CYP 2B6 in predicting the incidence and 
severity of ketamine induced EP 
To investigate Aim 3, an interaction term CYP2B6*GRIND2B genotypes will be added to 
the logistic and linear regression models described above. Significant Type III Sums of Squares 
for the interaction term indicates gene-gene interaction effects for incidence of ketamine-induced 
EP and/or EP severity. 
Aim 4. Evaluate the validity of the CADSS in discriminating EP behaviors associated with 
ketamine use. 
The frequency and degree of EP will be compared between the group of patients who 
received ketamine and those who did not. Significance will be p < .10 (two-tailed) for this 
analysis to reduce the probability of a type II error as a result of the small sample size. When 
analyzing data from exploratory studies not fully powered it is acceptable to increase the level of 
significance (Campbell, 2005; Cohen, 1994). 
Confounding Variables 
Possible confounding variables include age and administration of midazolam. Due to the 
potential confounding of age, post-hoc analyses will be performed in which the subjects are 
stratified by age for the Chi-square analyses and comparisons made between the age-specific 
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odds ratios. Premedication with midazolam prevents the determination of genetic effect due to 
ketamine alone. Given that many patients receive midazolam preoperatively for anxiolysis, 
determination of genetic effects of ketamine in the context of premedication with midazolam will 
produce generalizable results to a real-world clinical scenario. Thus, determination of genetic 
predisposition to EP, despite the administration of midazolam will closely mimic current clinical 
practice.  
Population stratification always exists as a confounding variable when participants in a 
genetic association study come from more than one subpopulation that differ in genotype 
frequency. The HWE will be used to assess for population stratification and any deviation 
corrected in the statistical analysis.  
Potential Problems, Alternate Strategies, and Limitations 
If for some reason, the UMass core Laboratory is not available, DNA samples will be 
transferred per IRB-approved biological transfer protocol, to Duke University’s Molecular Core 
Facility in the Duke Molecular Physiology institute where the PI’s primary mentor is based. If 
recruitment into the study is inadequate, the surgeons will contacted to introduce the study to the 
patients. In addition, the study protocol will be expanded to cover procedures performed at other 
UMass facilities and affiliated hospitals such as UMass Memorial campus, and Marlboro 
Hospital. 
The limitations of this study include that (1) the gene-environment, gene-gene, and drug-
drug interactions will not be completely controlled, (2) nonrandom sample will limit 
generalizability, and (3) the indirect effect of other genes is not investigated. Data analysis will 
control for all drug administered during the perioperative period, while genetics analysis will 
include analysis of linkage disequilibrium. In addition, patients taking drugs that are known to 
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inhibit the CYB2B6 enzyme will be excluded from the study. Given that the application has no a 
priori knowledge of which patients will develop EP or will have a particular candidate gene, the 
risk of bias due to non random sampling is greatly reduced. In addition, extra effort will be made 
to recruit a diverse population especially women and minorities.  
 
  
24 
 
PROTECTION OF HUMAN SUBJECTS 
This study protocol will be reviewed and approved by the University of Massachusetts, 
Worcester) Institutional Review Board (IRB). Every effort will be made to protect participant’s 
privacy and confidentiality, and minimize risk. Written informed consent will be obtained prior 
to enrollment and collection of any data. The four essential elements of valid informed consent 
will be employed in the consent process: a) provision of all relevant information about the study, 
d) making the sure the information is understood,  c) ensuring that potential participants are 
capable of consenting and d) ensuring that potential participant are not coerced (Vijverberg, 
Pieters, & Cornel, 2012). The PI has completed CITI training on ethical and responsible 
research. All data collected will be de-identified, and the investigators will comply with Health 
Insurance Portability and Accountability Act of 1996 (HIPPA) regulations. 
Participants will have the right to withdraw from the study, or decline to answer specific 
questions at any point. Should the participant become distressed, or uncomfortable during 
assessments, the assessment will be terminated with the option of completing later left to the 
participant. The PI will attempt to comfort such participants and provide any helpful 
explanations. If the discomfort or distress is related to the surgery and not the study assessments, 
the PI will immediately notify the nurse and/or anesthesia provider. 
There are no anticipated physical risks to participants. However, there is a chance that 
venous blood cannot be obtained from the established IV access. In that instance, venous blood 
will be obtained by direct veni-puncture. This risk will be included in the informed consent and 
discussed with participants in advance. Blood samples will be stored in the locked research 
freezer at UMMS, accessible only to laboratory personnel and the PI. All samples will be 
stripped of personal identifiers and only the PI will have access to the single master file linking 
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the research ID number on the sample, data sheets and the participants’ name. No additional, 
genetic profiling will be carried out on the samples, except those stated in this research protocol. 
Samples from participants who provide additional written consent will be stored for future 
research studies. Samples from participants who do not provide the additional written consent 
will be destroyed at the completion of the study. Separate IRB approval will obtained for future 
analysis on stored samples.  
There is always the potential for breach of confidentiality when study instruments are 
completed but this risk will be greatly minimized by using unique research ID number. All 
information provided by the participants will be referenced to a unique research ID number. And 
all paper data forms will be stored in a secure locked cabinet within a locked office, accessible 
only to the PI, while electronic data will be stored in a UMASS password protected, encrypted R 
drive assigned to the PI.  
The clinical expertise of the applicant is anticipated to limit the potential risk to 
participants. All study participants will be monitored for risks related to study participations. No 
results will ever be reported in a personally identifiable manner, only grouped data will be 
presented in presentations and publications. The usual standards for medical confidentiality will 
be observed.  
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EXECUTIVE SUMMARY 
 
A pilot study of the pharmacogenetics of ketamine-induced emergence phenomena: 
A Dissertation Presented by 
Edwin N. Aroke 
University of Massachusetts, Worcester  
 
This study explored the relationship between single nucleotide polymorphisms in the 
cytochrome p450 (CYP 2B6)  and N-Methyl-D-Aspartate receptor  (GRIN2B) genes, and the 
incidence and severity of ketamine-induced emergence phenomena (EP) in relatively healthy 
patients. Table 3 below summarizes the changes made to the original research proposal approach 
and rationale for the changes.  
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Table 3 
Summary of changes to dissertation proposal 
Original Proposal Change Rationale for the Changes 
Title: Exploring the 
Pharmacogenetics of 
Ketamine-Induced 
Emergence Phenomena 
Exploring the 
Pharmacogenetics of 
Ketamine-Induced Emergence 
Phenomena: A Pilot Study 
The title was changed to better 
reflect the nature of the study. 
In addition, sample size for 
reduced. 
Sample size of 135 Sample size of 75 Sample size was reduced 
because of cost, time constraints 
and lack of pilot data to justify 
the full study.  
Participants will include 
healthy patients undergoing 
hand or foot surgery.  
Participants included patients 
undergoing minor orthopedic, 
hand, foot and anorectal 
procedures.  
Increasing the number of 
surgical procedures potential 
participants were recruited from, 
reduced recruitment time and 
time needed to complete the 
study. 
On the eve of the scheduled 
surgical procedure, the PI 
will call potential 
participants to discuss the 
study.  
No potential participants were 
called on the eve of the 
surgical procedure. 
Calling of potential participants 
was discouraged by IRB staff.  
When the potential 
participants present for 
surgery they will undergo 
routine pre-procedure 
assessment by the SACU 
nurse and anesthesia 
provider. 
 After this, the PI will 
discuss the study with them 
and review all components 
of the consent form, 
including the study purpose, 
procedures, potential risks 
and benefits. 
When the potential 
participants presented for 
surgery they underwent 
routine pre-procedure 
assessment by the SACU 
nurse and anesthesia provider. 
At the end of the assessment, 
the nurse asked potential 
participants their willingness 
to discuss the study with the 
PI.  
The PI discussed the study 
with willing potential 
participants, and reviewed all 
components of the consent 
form, including the study 
purpose, procedures, potential 
risks and benefits 
This additional step was 
necessary to ensure that only 
willing potential participants 
were approached by the PI. This 
gave them the chance to opt-out 
of the study even before meeting 
the PI. This was a vital step in 
the consent process because the 
PI works in the same facility as a 
Nurse Anesthetist. It ensured 
that participation all aspects of 
the study was completely 
voluntary.  
Consenting participants will 
be asked to complete a paper 
and pencil demographic 
form  with information 
about their age, race, 
All forms (demographic form, 
CADSS scale, and Data 
collection sheets) were 
completed on all subjects on a 
secured web-based 
Use of REDCaps reduced 
potential errors that could be 
introduced during transcription 
of pencil and paper surveys. 
Data can be verified easily by 
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smoking history, alcohol 
use, highest level of 
education and gender 
application: REDCaps, and 
downloaded onto a UMass 
secure drive that is backed up 
daily. 
Committee chair and data can be 
downloaded easily to SPSS for 
analysis.  
Standard of care allows for 
many alternative anesthetics 
to be used to achieve intra-
operative sedation. The 
anesthesia provider will 
determine the choice of 
anesthetic.   
Standard of care allows for 
many alternative anesthetics 
to be used to achieve intra-
operative sedation. The 
anesthesia provider 
determined the choice of 
anesthetic.   
However, if the provider 
chose to use ketamine, they 
administered the standard 
dose of 0.5mg/kg. To ensure 
patient safety and comfort 
other medications were 
administered at the discretion 
of the anesthesia provider. 
The dose of 0.5mg/kg of 
ketamine is typically 
administered as an adjunct for 
pain management and during 
sedation.  
Standardizing the dose helped 
control the effect of dosage on 
EP. 
Samples will be frozen on 
ice and transported to 
UMass core laboratory, 
where it will be stored 
frozen at -20 degrees  
centigrade until analyzed 
Samples were stored at -20 
degrees for about one month, 
then moved to -80 degrees 
freezer in batches for long 
term storage. 
DNA is more stable at -80 
degrees than -20 degrees 
centigrade. 
DNA extraction and 
genotyping will be at a 
UMASS based molecular 
biology laboratory. 
DNA extraction was 
performed at a UMASS based 
laboratory.  
The extracted DNA was 
shipped to Duke University 
were the genotyping was done 
at the Duke Molecular 
Physiology Institute. 
The cost of genotyping was 
much lower at Duke University 
compared to UMASS. 
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DISSERTATION DEFENSE SLIDES 
A Pilot Study of the Pharmacogenetics of 
Ketamine-Induced Emergence Phenomena: 
A Dissertation
Edwin Aroke
April 21st 2016
Graduate School of Nursing
University of Massachusetts  Worcester
 
Background and Significance
• Up to 55% of patients administered ketamine experience 
Emergence Phenomena (EP)
 EP is characterized by dissociative symptoms and mimics 
schizophrenia
 EP may increase risk of injury, prolong hospital stay, increase 
nursing care requirement and cost, and lower satisfaction.
• Genetics account for about 50% of severe adverse drug 
reactions
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Purpose
To investigate genetic association between 
CYP2B6 and GRIN2B single nucleotide 
polymorphisms (SNPs) and the incidence and 
severity of ketamine-induced EP in healthy 
patients
 
Specific Aims
1. Explore genetic association between CYP 2B6 SNPs and ketamine-
induced EP
2. Explore genetic association between GRIN 2B SNPs and ketamine-
induced EP
3. Evaluate effect of ketamine-induced EP on patient satisfaction with 
anesthesia
4. Determine effect size of ketamine-induced EP
5. Evaluate the accuracy of Clinician Administered Dissociative State Scale 
(CADSS) in discriminating ketamine-induced EP from other post-
anesthetic behaviors. 
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Methods
Cross sectional candidate gene 
pharmacogenetic association study
IRB approval was obtained from UMMS IRB
 
Inclusion and Exclusion Criteria
Inclusion
ASA 1 &2
Read and write English
Adults 18 years and 
older
 Scheduled for minor 
orthopedic, hand, foot 
or anorectal surgery 
with sedation
Exclusion
History of depression, 
bipolar disorder and 
schizophrenia
Contraindications to 
ketamine e.g. uncontrolled 
hypertension, history of 
ketamine addiction
Current use of Rifampicin, 
Dilantin or Phenobarbital 
Pregnancy
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Characteristics of study participants: 
No demographic differences between various groups
No Ketamine No EP Ketamine EP Ketamine
P-valuesa P-valuesb
N = 28
(37.3%)
N = 28
(37.3%)
N = 19
(25.3%)
Characteristics Mean (SD)
Age (years) 51.89 (13.57) 51.04 (13.02) 47.84 (16.04) 0.522 0.456
Body Mass Index (kg/m2) 29.99 (6.61) 27.23 (5.43) 28.28 (4.98) 0.095 0.503
N (%)
Gender 
Males
Female
11 (39.3)
17 (60.7)
15 (53.6)
13 (46.4)
9 (47.4)
10 (52.6)
0.323
0.676
Race 
White or Caucasian
Asian
Black or African American
More than one Race
Unknown/Not Reported
22 (78.6)
1 (3.6)
2 (7.1) 
1 (3.6) 
2 (7.1)
26 (92.9)
1 (3.6)
1 (3.6)
0
0
16 (84.2) 
1 (5.3)
1 (5.3)
0
1 (5.3)
0.455 0.651
Ethnicity (N, %)
Hispanic 
Non-Hispanic
3 (10.7)
24 (85.7)
2 (7.1)
26 (92.9)
2 (10.5)
17 (89.5)
0.599 1.000
Education (N, %)
Less than High School
High School certificate
Some college
Bachelor degree
Master degree
Professional/Doctorate
1 (3.6) 
8 28.6)
14 (50.0)
3 10.7)
2 (7.1)
0
1 (3.6)
9 32.1)
5 (17.9)
8 28.6)
2 (7.1)
3 10.7)
1 (5.3)
5 (26.3)
5 (26.3)
3 (15.8)
26.3 (5)
0
0.131 0.301
a:  Ketamine cases versus Non-ketamine controls
b: Patients exposed to Ketamine who experienced EP (cases) versus patients who did not experience EP (Controls) 
 
Validation of the Clinician Administered Dissociative State Scale (CADSS): 
CADSS has a Cronbach’s alpha of 0.82 and reliably discriminated ketamine-
induced EP from other variables
Difference in Severity of Dissociation by ketamine Administration
Total CADSS Score
x̄ sd Median U p
No Ketamine (n = 28) 1.0 1.78 0
328 <0.001
Ketamine (n= 47) 4.74 5.59 3
Male (n = 35) 3.4 5.35 1
670.5 0.750
Female (n = 40) 3.3 4.52 2
Occurrence of Ketamine-Induced Emergence Phenomena 
No EP EP Fisher’s exact
p-value
OR (95% CI)
n % n  %
No Ketamine (n= 28) 26 92.9 2 7.1
0.003 8.821 (1.869, 41.634)
Ketamine (n= 47) 28 59.6 19 40.4
Male (n= 35) 26 74.3 9 25.7
0.798 0.808 ( 0.292, 2.231)
Female (n= 40) 28 70 12 30
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Hardy Weinberg Equilibrium
 
Using Logistic Regression to Predict EP Occurrence
Predictor Wald 
p-value
OR 90% CI Model χ2 Model
p value
Nagelkerke’s
R2
Prediction
rs3745274 0.313 2.758 0.528 14.398
19.389 0.002 0.477 77.8
Age 0.051 0.932 0.879 0.989
Duration of 
Anesthesia
0.021 1.050 1.014 1.087
Ketamine dose 0.003 1.161 1.069 1.261
Time to CADSS 0.012 0.939 0.901 0.978
rs2279343 0.587 0.561 0.310 10.233
23.098 <0.001 0.559 79.5
Age 0.040 0.922 0.864 0.984
Duration of 
Anesthesia
0.013 1.064 1.021 1.110
Ketamine dose 0.002 1.193 1.085 1.312
Time to CADSS 0.010 0.929 0.886 0.973
rs1019385 0.668 1.529 0.301 7.776
18.468 0.002 0.458 77.8
Age 0.066 0.943 0.895 994
Duration of 
Anesthesia
0.026 1.053 1.014 1.094
Ketamine Dose 0.002 1.142 1.064 1.226
Time to CADSS 0.019 0.941 0.901 0.982
rs1806191 0.672 0.685 0.158 2.973
8.458 0.002 0.458 80
Age 0.064 0.944 0.897 0.994
Duration of 
Anesthesia
0.025 1.052 1.014 1.092
Ketamine dose 0.002 1.138 1.063 1.219
Time to CADSS 0.017 0.942 0.903 0.982
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Using Logistic Regression to Predict EP Occurrence: 
Non-genetic variable significantly predicted the occurrence of EP 
OR Wald 
p-value
90% CI Model 
χ2
Model 
p value
Nagelkerke’s
R2
Prediction
Ketamine 
dose
1.135 0.002 1.063 1.211
18.251 0.001 0.435 76.6
Age 0.952 0.093 0.907 0.999
Duration of 
Anesthesia
1.044 0.033 1.010 1.078
Time to 
CADSS
0.949 0.020 0.915 0.985
 
Using Linear Regression to Prediction EP Severity: 
Non-Genetic variables significantly predicted the severity of EP
Predictor B β P 
value
90% CI F Model
p 
value
R2
Adjusted
R2
Ketamine dose 0.048 0.527 0.001 0.026 0.070
4.028 0.007 0.277 0.208
Duration of 
Anesthesia
0.016 0.457 0.056 0.002 0.030
Age -0.025 -0.264 0.057 -0.046 0.004
Time to CADSS -0.019 -0.509 0.042 -.0.34 -0.004
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Highlights
Non genetic variables significantly predicted 
occurrence and severity of EP
 OR of EP with ketamine dose= 1.135
 Adjusted R2 for EP severity = 20.8%
EP does not affect patient satisfaction with the 
anesthetic
 
Implications for Clinical practice
Use ketamine when appropriate
Closely monitor patients
Titrate dose carefully
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Implications for Research
Feasibility of Approach
Sample Size estimation
 
Implications for Research
dbSNP ID MAF OR Sample 
Size a
Adjusted 
OR b
Sample
Size a
rs3745274 0.26 1.125 384 2.7 78
rs2279343 0.28 1.48 390 1.8 138
rs1019385 0.50 1.41 570 1.5 570
rs1806191 0.50 1.25 570 1.5 570
MAF = Minor allele frequency; OR = gene only odds ratio to EP occurrence, 
a = sample size for cases only (match for control to obtain total sample size)
b = Odds ratio of EP occurrence by genotype adjusted for ketamine dose, age, duration of surgery, time from 
ketamine administration to assessment of dissociation
 Feasibility of approach
 Sample size estimation
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Limitations
Small Sample Size
Caucasian, middle aged and well educated
Other SNPs in CYP2B6 and GRIN2B genes
Ketamine metabolites
 
Strengths
Stringent inclusion and exclusion criteria
Real live clinical setting
One observer
Genotype controls
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Conclusion
Conduction of a well powered pharmacogenetic 
study is feasible
Despite concerns by providers, ketamine-induced 
EP does not seem to affect satisfaction with the 
anesthetic
The odds of EP occurrence are 3.52 times higher 
with every additional 1ml (10mg) of ketamine
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DISSEMINATION PLAN 
The primary description of this dissertation work has been submitted as a manuscript on April 
30th 2016 to Nursing Research for review and consideration for publication. A podium 
presentation “Lack of Association of CYP2B6*6 And GRIN2B Alleles with Ketamine-Induced 
Emergence Phenomena: A pilot Study” will be presented on August 5th 2016 at the International 
Society of Nurses in Genetic (ISONG) World Congress, Dublin, Ireland. 
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APPENDIX 
Demographic Sheet 
Please do not write your name on this form. This information will allow us to describe all the 
people who took part in the study. 
Study ID       ________________________ 
Date of birth       ________________________ 
Age (years)      ________________________ 
Gender       
o Female 
o  Male 
o  Transgender  
Ethnicity 
o Hispanic or Latino 
o Not Hispanic or Latino 
o Unknown / Not Reported 
Race  
o Caucasian 
o Asian  
o Black or African American 
o American Indian 
o Other  
Do you currently smoke? 
o Yes 
o No  
If Yes, How many packs per day    ______________________ 
 Have you EVER smoked?  
o Yes 
o No 
When did you quit? 
o Less than 1 month ago 
o 1 month to 1 year ago 
o 1 year to 5years ago 
o Over 5 years ago 
Do you smoke marijuana? 
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o Yes 
o No 
Do you use any other recreational drugs? 
o Yes 
o No 
Please list recreational drugs      ______________________  
Do you drink alcohol every day?  
o Yes 
o  No 
How much in a typical week?    _______________________ 
What is your highest level of education completed? 
o Did Not Complete High School 
o High School/GED 
o Some College 
o Bachelor's Degree 
o Master's Degree 
o  Advanced Graduate work or Doctorate  
Weight (kilograms)     ________________________ 
Height (cm)      ________________________ 
BMI       ________________________ 
Comments      ________________________  
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Data Collection Sheet 
Study ID        ________________________ 
CADSS time (Copy from CADSS form)                                            ________________________ 
PACU Arrival time       ________________________ 
Weight (Kg)        ________________________ 
Height (cm)        ________________________ 
Ketamine Time       ________________________ 
Ketamine (mg)       ________________________ 
Ketamine (mg/kg)       ________________________ 
Midazolam (mg)       ________________________ 
Midazolam (mg/kg)       ________________________ 
PACU to CADSS time      ________________________ 
Type of Procedure       ________________________ 
Time since last dose of Ketamine (mins)     ________________________ 
Duration of Anesthesia (mins)      ________________________ 
Other Sedatives (mg)        ________________________ 
Other Perioperative Medications (Name and Dose)    ________________________ 
         ________________________ 
Anesthesia Complications       ________________________ 
Current Medications        ________________________ 
Other Co-morbidities        ________________________ 
Comments        ________________________ 
Duration in PACU (minutes)      ________________________ 
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Clinician Administered Dissociative States Scale (CADSS) 
 
 Subjective Items:  
1. Do things seem to be moving in slow motion?  
0= Not at all.  
1= Mild, things seem slightly slowed down, but not very noticeable.  
2= Moderate, things are moving about twice as slow as normally.  
3= Severe, things are moving so slowly that they are barely moving.  
4= Extreme, things are moving so slowly, I have the perception that everything has come 
to a stop, as if time is standing still.  
 
2. Do things seem to be unreal to you, as if you are in a dream?  
0= Not at all.  
1= Mild, things seem a little unreal, but I’m well aware of where I’m at.  
2= Moderate, things seem dreamlike, although I know I am awake.  
3= Severe, things seem very dreamlike, although I know that I am here, I have the feeling 
like I might be asleep.  
4= Extreme, I feel like nothing is real, like I should pinch myself to wake up, or ask 
someone if this is a dream. 
  
3. Do you have some experience that separates you from what is happening; for instance, do you 
feel as if you are in a movie or a play, or as if you are a robot?  
0= Not at all.  
1= Mild, I feel a little bit separated from what is happening, but I am basically here. 2= 
Moderate, I feel somewhat separated from what is going on, or I feel as if I am in a 
movie or a play.  
3= Severe, I feel extremely separated from what is going on, or I feel as if I am in a 
movie or a play.  
4= Extreme, I feel as if everyone around me is talking a foreign language, so that I cannot 
understand what they are saying, or I feel as if I am on the outside looking in, or like I 
am a robot or a machine.  
 
4. Do you feel as if you are looking at things from outside of your body?  
0= Not at all.  
1= Mild, I feel somewhat disconnected from myself, but I am basically all together. 2= 
Moderate, I feel like I am outside of my body, but not looking down upon myself from 
far above.  
3= Severe, I feel like I am twenty feet or more away from my body, looking down from 
above.  
4= Extreme, I feel as if I am hundreds of feet above myself, looking down at myself and 
everyone else here.  
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5. Do you feel as if you are watching the situation as an observer or a spectator?  
0= Not at all.  
1= Mild, I feel slightly detached from what is going on, but I am basically here.  
2= Moderate, I feel somewhat removed as an observer or a spectator, but I am definitely 
in this room.  
3= Severe, I feel very much as if I am an observer or a spectator, but I am still here in this 
room.  
4= Extreme, I feel completely removed from what is happening, as if I am not a part of 
this experience in any way, but totally removed from what is happening, as an 
observer or a spectator. 
 
6. Do you feel disconnected from your own body?  
0= Not at all.  
1= Mild, I feel a little bit disconnected from myself, but I am basically all here.  
2= Moderate, I feel somewhat detached from my own body, but I am basically all 
together.  
3= Severe, I feel detached from my own body, but not far removed from by body, and I 
feel as if it is me there.  
4= Extreme, I feel like I am completely out of my body, as if I am looking at my own 
body from a long way off, as if there is another person there.  
 
7. Does your sense of your own body feel changed: for instance, does your own body feel 
unusually large or unusually small?  
0= Not at all.  
1= Mild, I have a vague feeling that something about my body has changed, but I can’t 
say exactly what it is.  
2= Moderate, I feel like my body has increased or decreased in size slightly, or that it 
feels somewhat as if it is not my body.  
3= Severe, I feel as if my body has increased to twice its normal size, or decreased to 
twice its normal size, or I very much feel that this is not my body.  
4= Extreme, I feel as if my body has swelled up to at least ten times its normal size, or as 
if it is ten times as small. Or as if my arms have become like toothpicks.  
 
8. Do people seem motionless, dead, or mechanical?  
0= Not at all.  
1= Mild, people seem a little bit more motionless, dead, or mechanical than would be 
normal.  
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2= Moderate, people seem to be at least twice as motionless or mechanical than would be 
normal.  
3= Severe, people seem to be barely moving, or barely alive, or very mechanical.  
4= Extreme, it’s as if everyone were frozen or completely like machines.  
 
9. Do objects look different than you would expect?  
0= Not at all.  
1= Mild, things seem slightly different than normal, although it is barely perceptible. 2= 
Moderate, things are somewhat distorted, but I have no problems recognizing things 
around me.  
3= Severe, things are much more distorted, but I have no problems recognizing things 
around me.  
4= Extreme, like everything is distorted, not real, I feel like I cannot recognize anything, 
everything is alien or strange.  
 
10. Do colors seem to be diminished in intensity?  
0= Not at all.  
1= Mild, things seem slightly paler than usual if I think about it.  
2= Moderate, colors are somewhat diminished, but still recognizable.  
3= Severe, colors are extremely pale, in no way as vivid as they usually are.  
4= Extreme, everything is black and white, or all the colors have been washed out.  
 
11. Do you see things as if you were in a tunnel, or looking through a wide angle photographic 
lens?  
0= Not at all.  
1= Mild, I feel a little bit like I am looking through a tunnel, or a wide angle lens.  
2= Moderate, the periphery of my vision is blacked out, but I still have most of my visual 
field, or things are somewhat like a wide angle lens.  
3= Severe, it seems as if I’m looking through a tunnel, or through a wide angle lens, but I 
can see everything clearly.  
4= Extreme, as if I’m looking through a pair of binoculars backwards, where everything 
around the periphery is blacked out, and I can see a little point of light at the end of a 
tunnel, with little tiny people and objects, or I am seeing things as if through a wide 
lens and things are incredibly expanded.  
 
12. Does this experience seem to take much longer than you would have expected?  
0= Not at all.  
1= Mild, it seems as if the interview has gone by for at least twice as long as the true 
elapsed time.  
2= Moderate, it seems as if the interview has gone by for at least two hours.  
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3= Severe, it seems as if at least ten hours have gone by since the start of the interview.  
4= Extreme, it seems as if time is standing still, so that we have been here at this point in 
time for ever. 
  
13. Do things seem to be happening very quickly, as if there is a lifetime in a moment?  
0= Not at all.  
1= Mild, things are happening slightly faster than normal.  
2= Moderate, things seem to be happening at least twice as fast as normal.  
3= Severe, things seem to be happening at least 10 times faster than normal.  
4= Extreme, as if this whole experience has happened at once, or as if there is a lifetime 
in a moment.  
 
14. Do things happen that you later cannot account for?  
0= Not at all.  
1= Mild, there may have been things which happened which now I can’t account for, but 
nothing pronounced.  
2= Moderate, at least once there were things which happened which now I can’t account 
for.  
3= Severe, at least twice I have lost several minutes of time, so that now there are things I 
cannot account for.  
4= Extreme, large pieces of time are missing, of ten minutes or more, so that I am 
confused about what has happened.  
 
 
15. Do you space out, or in some other way lose track of what was going on?  
0= Not at all.  
1= Mild, I have had some episodes of losing track of what is going on, but I have 
followed everything for the most part.  
2= Moderate, I have lost at least a minute of time, or have completely lost track of what is 
going on now.  
3= Severe, I have lost several segments of time of one minute or more.  
4= Extreme, I have lost large segments of time of at least 15 minutes or more.  
 
 
 
16. Do sounds almost disappear or become much stronger than you would have expected?  
0= Not at all.  
1= Mild, things are a little quieter than normal, or a little louder than normal, but it is not 
very noticeable.  
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2= Moderate, things have become about twice as soft as normal, or twice as loud as 
normal.  
3= Severe, things have become very quiet, as if everyone is whispering, or things have 
become very loud (although not deafening).  
4= Extreme, things have become completely silent, or sounds are so loud that it is 
deafening, and I feel as if I am going to break my eardrums.  
 
17. Do things seem to be very real, as if there is a special sense of clarity?  
0= Not at all.  
1= Mild, things seem to be a little bit more real than normal.  
2= Moderate, things seem to be more real than normal.  
3= Severe, things seem to be very real or have a special sense of clarity.  
4= Extreme, things seem to have an incredible sense of realness or clarity.  
 
18. Does it seem as if you are looking at the world through a fog, so that people and objects 
appear far away or unclear?  
0= Not at all.  
1= Mild, things seem somewhat foggy and unclear, or I do have the feeling that things are 
far away, but there is not a major effect on how I perceive things around me.  
2= Moderate, things seem very foggy and unclear, or things seem like they are far away, 
but I can identify the interviewer and objects in the room easily.  
3= Severe, I can barely see things around me, such as the interviewer and the objects in 
the room.  
4= Extreme, I cannot make out anything around me.  
 
19. Do colors seem much brighter than you would have expected?  
0= Not at all.  
1= Mild, colors seem a little bit brighter than normal, but not more than twice as bright.  
2= Moderate, colors seem brighter, about twice as bright as normal.  
3= Severe, colors seem very bright, at least five times as bright as normal.  
4= Extreme, colors seem extremely bright, almost fluorescent, at least 10 times as bright 
as normal.  
 
20. Do you feel confused about who you really are?  
0= Not at all.  
1= Mild, I feel a little bit confused about who I am.  
2= Moderate, I feel confused about who I am, but I basically know who I am.  
3= Severe, I feel very confused about who I am, and at times I wonder if I am a person, 
or if I am many people.  
4= Extreme, I feel as if there were two or more sides to myself.  
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21. Do you feel like there are different parts of yourself which do not fit together?  
0= Not at all.  
1= mild, I feel like there are different sides of myself, but they’re basically part of myself.  
2= Moderate, I feel like I have different parts which don’t quite fit together.  
3= Severe, there are two or more sides to myself which have unique characteristics.  
4= Extreme, I have two or more parts to myself with unique personality characteristics.  
 
22. Do you have gaps in your memory?  
0= Not at all.  
1= Mild, there are some recent things which I cannot remember.  
2= Moderate, there have been a few gaps in my memory which lasted a few minutes.  
3= Severe, there have been large gaps in my memory which lasted for more than a few 
minutes.  
4= Extreme, I cannot piece together what is happening from one moment to the next due 
to large gaps in my memory.  
 
23. Do you feel like you have more than one identity?  
0= Not at all.  
1= Mild, I feel like there is more to me than my personality, but it’s basically part of my 
identity.  
2= Moderate, I feel like I have more than one personality, but the personalities are not 
really distinct.  
3= Severe, I have two or more personalities, although they are not fully developed as 
distinct entities.  
4= Extreme, I have two or more personalities which are distinct and have their own 
names and other unique characteristics.  
 
 
Supplemental Question: 
29. If presented with a choice in the future, will you accept the same anesthetic? 
 _____ NO  
 _____ I don’t know 
 _____ Yes 
30. On a scale of 1 to 100 how satisfied were you with the anesthetic? _______________ 
 1= not satisfied at all.  
100= extremely satisfied 
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Observer Items:  
24. Did the subject seem eery or strange, or in some other way give you an uncomfortable 
feeling?  
0= Not at all.  
1= Mild, the subject seemed a little bit eery or strange.  
2= Moderate, the subject seemed somewhat eery and strange and gave me an 
uncomfortable feeling.  
3= Severe, the subject seemed very eery and strange and I was very uncomfortable sitting 
with this person.  
4= Extreme, the subject seemed very eery and strange and I was extremely uncomfortable 
sitting with this person.  
 
25. Did the subject blank out or space out, or in some other way appear to have lost track of what 
was going on?  
0= Not at all.  
1= Mild, the subject seemed a little bit out of it, but not very noticeable.  
2= Moderate, the subject on more than one occasion spaced out, blanked out, or in some 
other way showed evidence of having lost some time.  
3= Severe, the subject at least twice blanked out, spaced out, or in some other way 
showed evidence of having lost some time.  
4= Extreme, the subject was continuously blanking out and losing track of what was 
going on.  
 
26. Did the subject appear to be separated or detached from what is going on, as if not a part of 
the experience or not responding in a way that you would expect?  
0= Not at all.  
1= Mild, somewhat detached from what was going on.  
2= Moderate, as if the subject is there but not there at the same time.  
3= Severe, so that the subject definitely appears to be detached from his or her 
surroundings.  
4= Extreme, appearing totally numbed out and not a part of what is going on around him 
or her.  
 
27. Has the subject had to be put back on track, or grounded in the here and now, during or soon 
after the experience?  
0= Not at all.  
1= Mild, the subject seemed a little bit out of it, but followed what we were doing and 
answered all of the questions appropriately.  
2= Moderate, at least once I had to tell the subject what we were doing or had to repeat a 
question.  
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3= Severe, at least once I had to tell the subject where he was or who he was, or two 
times or more I had to tell the subject what we were doing, or two times or more I had 
to repeat questions.  
4= Extreme, I was continuously reminding the subject of what we were doing, or had to 
tell the subject more than once where he was or who he was, or was continuously 
repeating questions.  
 
28. Did it seem as if there were different aspects of the subject’s personality which did not fit 
together?  
0= Not at all, the subject’s personality was very clear.  
1= Mild, sometimes the subject would do or say something which didn’t seem to fit in 
with their personality.  
2= Moderate, the subject sometimes talked or acted in different ways.  
3= Severe, there seemed to be different parts of the subject’s personality which did not fit 
in with the whole.  
4= Extreme, the subject specifically referred to two different aspects of their personality 
and showed some evidence of more than one unique personality. 
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Study Flyer 
 
 
 
Are you an adult having anorectal, hand or foot surgery 
at UMass Memorial, Hahnemann, or University Campus?  
You may be asked to be in a research study to better 
understand why people who get ketamine (a drug for 
anesthesia) during surgery may have different responses. 
The researcher will be present on the day of your surgery 
to discuss the study with you, answer all your questions, 
and ask for your consent to participate.  
                                             Thank You 
 
Principal Investigator 
Edwin N. Aroke, MSN, CRNA,  
PhD Candidate, Graduate School of Nursing 
UMASS, Worcester 
Tel: (617) 818 0585 
 
Pharmacogenetics of Ketamine-
Induced Emergence Phenomena:  
A Pilot Study 
 
IRB ID# H00007484 


